View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 20, 2021

MedRhythms and EVERSANA to launch software-based device for stroke 

MedRhythms and EVERSANA collaborate to market MR-001 for treating chronic stroke walking impairments.

MedRhythms has entered a collaboration with EVERSANA to launch and market its software-based medical device, MR-001, to treat chronic stroke walking impairments.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

The US-based digital therapeutics company, MedRhythms, received the US Food and Drug Administration’s breakthrough device designation for MR-001 in June last year.

Stroke is a major cause of disability in the US with over half of the survivors developing lasting walking deficits that have no standard of care. These long-term functional deficits can have a negative impact on the stroke survivor’s life.

Last month, MedRhythms commenced a clinical trial to assess the effect of MR-001 on acute stroke walking outcomes. The trial is being carried out along with UMass Memorial Healthcare.

MedRhythms president and co-founder Owen McCarthy said: “Today’s announcement marks a significant milestone in our commitment to serve chronic stroke survivors who have waited lifetimes for a standard of care.

“After years of development and testing, we stand ready to successfully launch this ground-breaking innovation with a best-in-class commercialisation partner.”

To facilitate the planned launch of the device, MedRhythms will use EVERSANA’s marketing services, which comprise market access, agency services and clinical and commercial field groups.

In addition, EVERSANA also provides medical science liaisons, channel management, patient services, compliance and health economics and outcomes research.

Each of these services is data and predictive analytics augmented, the company noted.

EVERSANA CEO Jim Lang said: “This breakthrough device demands a breakthrough, transformative approach to launch and commercialisation.

“We’re ready to deploy the full power of our infrastructure and experts to navigate the complexities of digital therapy launches to ensure this innovation quickly reaches the millions of chronic stroke patients desperately in need of treatment and a better quality of life.”

In 2019, MedRhythms launched its five-site randomised controlled trial at rehabilitation hospitals and research centres to examine the device.

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network